Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01169090 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy
A Phase 2 study, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 620
- Enrollment target
NCT01169090 is a Phase 2 study that has completed, run by Kowa Research Institute. The registered enrollment target is 620 participants.
The verdict
NCT01169090, a Phase 2 study, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 620 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a range of doses of SK-0403 in subjects with type 2 diabetes that are not adequately controlled on metformin alone.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG SK-0403
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01169090
The ClinicalTrials.gov registry entry for NCT01169090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 620 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01169090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01169090 about?
NCT01169090 is a clinical study titled "A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy". The purpose of this study is to evaluate the safety and efficacy of a range of doses of SK-0403 in subjects with type 2 diabetes that are not adequately controlled on metformin alone.
What is the current status of trial NCT01169090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 620 participants. The study started on 2010-07. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01169090?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), SK-0403 (DRUG).
Who is sponsoring clinical trial NCT01169090?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.